Mr. Gould is a Senior Principal in CBPartners' Value, Access, and Pricing practice, where he leads the U.S. Center of Excellence and focuses on managed markets strategy engagements. His experience has emphasized the development of numerous pricing and access strategies for both pre-launch and in-line assets within the U.S. Specifically, Mr. Gould supports asset development through various engagements, including: early stage / launch pricing, innovative and traditional contracting strategy, market access assessment, target product profile & optimized trial design review, and value message development / testing.
Mr. Gould also has extensive experience engaging with payers and other healthcare stakeholders through various qualitative research methodologies, including in-depth interviews, dyads, live panels / ad-boards, and virtual panels. Additionally, he has led engagements involving quantitative surveys and comprehensive data analyses.
Prior to joining CBPartners, Mr. Gould spent over five years with PriceSpective (ICON). Mr. Gould holds a MS in Biotechnology from Middle Tennessee State University and a BS in Biomedical Science from Auburn University.
Since its inception over 30 years ago, the 340B drug pricing program policy has evolved allowing for unprecedented expansion and influence. With this it has also become highly contested, especially in recent years as more legislation has been put forward to close 340B loopholes.
A research poster identifying instances where manufacturer HEOR data and/or pharmacoeconomic models either influenced positive changes, or had limited tangible impact on resultant US payer coverage decisions.